tailieunhanh - Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform efectively EMVI and MRF from positive to negative: Results of a long-term single center phase 2 clinical trial

Chemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to evaluate the efficacy and safety of neoadjuvant triplet chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in LARC. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG